Home / Resource Library / Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma

Indirect comparison of zanubrutinib and acalabrutinib for treatment of relapsed MCL.